BTKi FAQ
Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

Released: March 31, 2022

Expiration: March 30, 2023

Jeffrey P. DONOTUSESharman
Jeffrey P. DONOTUSESharman, MD
Jeff DONOTUSESharman
Jeff DONOTUSESharman, MD
Matthew S. Davids
Matthew S. Davids, MD, MMSc
Anthony Mato
Anthony Mato, MD, MSCE

Activity

Progress
1
Course Completed

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

  • For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
  • What is the optimal therapy for a patient with del(17p) CLL?
  • When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
  • What are best practices in the use of BTK inhibitors for patients with MCL?
  • How can BTK inhibitor resistance occur?
  • How might investigational noncovalent BTK inhibitors be used should they be approved?

What are key adverse events with BTK inhibitors?